OCULAR THERAPEUTIX, INC (OCUL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 25M 50M 75M FY16: 1.9M FY17: 1.9M FY18: 2M FY19: 4.2M FY20: 17.4M FY21: 43.5M FY22: 51.5M FY23: 58.4M FY24: 63.7M FY25: 52M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 20M 40M 60M FY17: 1.5M FY18: 1.5M FY19: 1.9M FY20: 15.3M FY21: 39.1M FY22: 47M FY23: 53.2M FY24: 58.1M FY25: 45.4M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-300M -200M -100M 0 100M 200M 300M FY16: -43.3M FY17: -61.9M FY18: -59.1M FY19: -85.8M FY20: -62.8M FY21: -78M FY22: -78.7M FY23: -82.4M FY24: -171.8M FY25: -270M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-300M -200M -100M 0 100M 200M 300M FY16: -44.7M FY17: -63.4M FY18: -60M FY19: -86.4M FY20: -155.6M FY21: -6.6M FY22: -71M FY23: -80.7M FY24: -193.5M FY25: -265.9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 2.5M 5M 7.5M FY17: 457K FY18: 465K FY19: 2.3M FY20: 2.1M FY21: 4.4M FY22: 4.5M FY23: 5.3M FY24: 5.6M FY25: 6.6M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-210M -140M -70M 0 70M 140M 210M FY16: -34M FY17: -50.5M FY18: -49.2M FY19: -77.6M FY20: -53.6M FY21: -65.5M FY22: -59.6M FY23: -70.2M FY24: -134.7M FY25: -204.9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-240M -160M -80M 0 80M 160M 240M FY16: -35.9M FY17: -58.7M FY18: -51.1M FY19: -79.8M FY20: -54.4M FY21: -66.7M FY22: -63.3M FY23: -76.3M FY24: -136M FY25: -216.9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 70M 140M 210M FY19: 45.3M FY20: 60.8M FY21: 82.2M FY22: 82.6M FY23: 85.6M FY24: 158.3M FY25: 187.2M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '13: -5.11 Q1 '14: -6.30 Q2 '14: -7.21 Q3 '14: -6.35 Q4 '14: -5.40 Q1 '15: -3.30 Q2 '15: -1.65 Q3 '15: -1.64 Q4 '15: -1.70 Q1 '16: -1.79 Q2 '16: -1.80 Q1 '17: -1.95 Q2 '17: -2.13 Q3 '17: -2.28 Q4 '17: -2.20 Q1 '18: -2.02 Q2 '18: -1.75 Q3 '18: -1.59 Q4 '18: -1.57 Q1 '19: -1.62 Q2 '19: -1.82 Q3 '19: -1.89 Q4 '19: -2.00 Q1 '20: -1.96 Q2 '20: -2.03 Q3 '20: -1.79 Q4 '20: -2.60 Q3 '22: -1.01 Q4 '22: -1.02 Q1 '23: -1.19 Q2 '23: -1.20 Q3 '24: -1.22 Q4 '24: -1.25 Q1 '25: -1.14 Q2 '25: -1.27 Q3 '25: -1.43 Q4 '25: -1.42 Q1 '26: -1.44 Q2 '26: -1.40 Q3 '14 Q4 '15 Q3 '17 Q4 '18 Q1 '20 Q4 '22 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.